Status:
COMPLETED
SREBP1 as a Potential Biomarker Promotes Cell Proliferation and Invasion in Thyroid Cancer
Lead Sponsor:
People's Hospital of Zhengzhou University
Conditions:
Thyroid Cancer
Eligibility:
All Genders
18-60 years
Brief Summary
In this study, the investigators detected the expression of SREBP1 in thyroid cancer tissues, explored the biological functions of SREBP1 in thyroid cancer cells.
Detailed Description
qRT-PCR and immunohistochemistry were used to detect the expression of SREBP1 in 96 pairs thyroid cancer tissues and the adjacent normal tissues. The following methods, including the MTS, colony-formi...
Eligibility Criteria
Inclusion
- Clinical diagnosis of thyroid cancer Reciving thyroidectomy surgery No experience of radiation therapy Nice treatment compliance and follow-up regularly
Exclusion
- Prior history of malignancy ; Radiotherapy history, chemotherapy history; Serious concomitant diseases ; Chronic renal insufficiency and liver dysfunction
Key Trial Info
Start Date :
January 16 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2018
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT04072731
Start Date
January 16 2016
End Date
January 1 2018
Last Update
August 28 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
the Affiliated Cancer Hospital of Xiangya Medical School
Changsha, Hunan, China, 410078